All stock lists
Aclaris Therapeutics, Inc. (ACRS)
United States · Delayed Price · Currency is USD
Pharmaceutical Preparations
3.81+0.06 (+1.73%)
Insider Score
––Not scored
ACRS Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
ACRS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 1.63 M | 2.00 M | 1.29 M | 3.30 M | 1.78 M |
| Revenue Growth (YoY) | -8.33 % | — | — | — | — |
| Cost of Revenue | 1.45 M | 1.79 M | 1.47 M | 2.45 M | 1.85 M |
| Gross Profit | 176.00 K | 208.00 K | -174.00 K | 850.00 K | -73.00 K |
| SG&A Expense | 6.05 M | 6.74 M | 5.58 M | 4.87 M | 5.39 M |
| R&D Expense | 18.07 M | 15.66 M | 16.58 M | 13.03 M | 11.45 M |
| Operating Expenses | 24.11 M | 22.40 M | 22.16 M | 17.90 M | 16.84 M |
| Operating Income | -23.94 M | -22.19 M | -22.33 M | -17.05 M | -16.91 M |
| Pretax Income | -21.50 M | -19.82 M | -19.80 M | -14.61 M | -15.43 M |
| Tax Provision | — | — | — | — | — |
| Net Income | -21.50 M | -19.82 M | -19.80 M | -14.61 M | -15.43 M |
| EPS (Basic) | -0.15 | -0.15 | -0.16 | -0.12 | -0.13 |
| EPS (Diluted) | -0.15 | -0.15 | -0.16 | -0.12 | -0.13 |
| Shares Outstanding | 142.74 M | 128.81 M | 122.66 M | 122.62 M | 122.58 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.